Collegium Pharmaceutical (COLL) vs Corvus Pharmaceuticals (CRVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Corvus Pharmaceuticals (CRVS) has outperformed Collegium Pharmaceutical (COLL) over the past year, gaining 12.8% versus a loss of 45.2%. Over five years, CRVS leads with a +183.6% price change compared with +37.7% for COLL. Corvus Pharmaceuticals is the larger company by market cap ($815.7 million vs $768.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COLL | CRVS |
|---|---|---|
| Share price | $24.72 | $9.67 |
| Market cap | $768.18M | $815.69M |
| 1-day change | -1.94% | -3.40% |
| YTD return | -46.61% | +25.58% |
| 1-year return | -45.24% | +12.84% |
| 5-year return | +37.72% | +183.58% |
| P/E ratio (TTM) | 22.68 | — |
| Forward P/E | 3.49 | — |
| EPS (TTM) | $1.09 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $780.57M | — |
| Revenue growth (YoY) | +23.62% | — |
| Net income (latest FY) | $62.87M | $-15.28M |
| Gross margin | 59.35% | — |
| Operating margin | 23.01% | — |
| Net margin | 8.05% | — |
| 52-week high | $50.79 | $26.95 |
| 52-week low | $21.43 | $6.39 |
| Distance from 52-week high | -51.33% | -64.12% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +77.99% | +225.75% |
| Average volume | 754.45K | 1.05M |
| Shares outstanding | 31.08M | 84.35M |
| Employees | 423 | 37 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRVS has outperformed COLL by 58.1 percentage points over the past year.
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
About Corvus Pharmaceuticals
CRVS stock →Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
COLL vs CRVS FAQ
Which is bigger, Collegium Pharmaceutical or Corvus Pharmaceuticals?
Corvus Pharmaceuticals (CRVS) is larger, with a market capitalization of $815.69M compared with $768.18M for Collegium Pharmaceutical (COLL).
Which stock has performed better over the past year, COLL or CRVS?
CRVS returned +12.84% over the past 12 months, compared with -45.24% for COLL (price return, excluding dividends). Past performance does not predict future results.
Are Collegium Pharmaceutical and Corvus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.